

Dr. David Samadi, prostate cancer expert, comments on drug found to slow advanced prostate cancer

drugs treating breast and ovarian cancer can come to save patients with advanced prostate cancer

NEW YORK, NEW YORK, UNITED STATES, May 4, 2020 / EINPresswire.com/ --

[Dr. David Samadi](#), prostate cancer expert, comments on drug found to slow advanced prostate cancer. According to a recent major clinical study, a drug used to treat breast and ovarian cancer shows promise in slowing progression of advanced prostate cancer.



Dr. David Samadi world renowned robotic surgeon

Men with advanced prostate cancer may have one more option to choose from to help slow the progression of their disease, according to Dr. [David Samadi](#), Director of Men's Health and urologic oncology at St. Francis Hospital on Long Island. Olaparib, a medication already approved to treat breast and ovarian cancers, has been found to be more effective than standard hormone treatments halting prostate cancer in its tracks. These findings are from the PROfound trial and have been published in the New England Journal of Medicine.

“

Prostate cancer affects over 200,000 lives of American Men. Screening has shown to save lives. Treating the disease early and contained to the prostate has survival benefit. Call 212 365 5000”

Dr. David Samadi

“This is excellent news for all men at risk for prostate cancer,” exclaimed Dr. David Samadi. “We know this drug has helped lengthen the lifespan of numerous women with breast or ovarian cancers. I’m encouraged and excited to see men with advanced prostate cancer can now benefit from these same gains.”

Olaparib, taken as a pill, works by inhibiting a protein called PARP which helps repair damaged DNA. Cancer cells are sometimes shaped by genetic mutations that rely on PARP to keep protect their DNA in order to keep growing. This drug works by blocking the activity of the PARP protein by zeroing in on cells with these DNA mutations. This results in cancer cell death putting the brakes on prostate cancer progression.


For the study, 387 men with advanced prostate cancer, were randomly selected to either olaparib or drugs used in standard hormone therapy treatment. Men receiving olaparib had a slowed progression of their disease by 5.8 months compared to 3.5 months of men using conventional hormone treatment.

“Cutting off cancer’s power to evolve is a game changer,” stated Dr. Samadi. “Olaparib is on the brink of becoming approved in the U.S. as the first genetically targeted treatment for prostate cancer.”

Dr. David Samadi is the Director of Men's Health and Urologic Oncology at St. Francis Hospital in Long Island. He's a renowned and highly successful board certified Urologic Oncologist Expert

and Robotic Surgeon in New York City, regarded as one of the leading prostate surgeons in the U.S., with a vast expertise in prostate cancer treatment and Robotic-Assisted Laparoscopic Prostatectomy. Visit Dr. Samadi's websites at [robotic oncology](#) and [prostate cancer 911](#).

Dr. David Samadi, M.D.
[roboticoncology](#)
+1 2123655000
[email us here](#)
Visit us on social media:
[Facebook](#)
[Twitter](#)
[LinkedIn](#)



robotic arm as good as human arm with full range of motion



Dr. David Samadi getting ready for da Vinci Prostate surgery

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.